Methamphetamine fails to alter the noradrenergic integrity of the heart

Ann N Y Acad Sci. 2008 Oct:1139:337-44. doi: 10.1196/annals.1432.017.

Abstract

The chronic use of methamphetamine leads to cardiomyopathy and a nigrostriatal dopamine deficiency that partly mimics what occurs in Parkinson's disease. This study examines the cardiac effects occurring after chronic administration of methamphetamine and parkinsonism-inducing neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Despite the similarities concerning the nigrostriatal dopamine denervation, methamphetamine failed to produce chronic norepinephrine depletion in the heart, thus contrasting with what occurs in Parkinson's disease or after administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. These data suggest that the chronic cardiovascular effects induced by methamphetamine rely on biochemical changes which differ from those activated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine or during the course of Parkinson's disease.

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / pharmacology
  • Adrenergic Agents / pharmacology*
  • Animals
  • Denervation
  • Dopamine Agonists / metabolism
  • Heart* / drug effects
  • Heart* / innervation
  • Heart* / physiology
  • Humans
  • Hypotension, Orthostatic
  • Levodopa / metabolism
  • Male
  • Methamphetamine / pharmacology*
  • Mice
  • Mice, Inbred C57BL
  • Neurotoxins / pharmacology
  • Norepinephrine / metabolism*
  • Parkinson Disease / metabolism
  • Parkinson Disease / pathology

Substances

  • Adrenergic Agents
  • Dopamine Agonists
  • Neurotoxins
  • Methamphetamine
  • Levodopa
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Norepinephrine